Trade

with

TrovaGene Inc
(NASDAQ: TROV)
AdChoices
4.43
-0.13
-2.85%
After Hours :
-
-
-

Open

4.56

Previous Close

4.56

Volume (Avg)

24.16k (165.14k)

Day's Range

4.36-4.59

52Wk Range

2.97-7.91

Market Cap.

83.74M

Dividend Rate ( Yield )

-

Beta

-0.73

Shares Outstanding

18.90M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-10.69M
Operating Margin
-4,123.71
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

20.92%

Top 10 Institutions

20.21%

Mutual Fund Ownership

5.15%

Float

85.36%

5% / Insider Ownership

2.65%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Carnegie Global Healthcare

  •  

    250,000

  • 0.00

  • 1.30

  • Vanguard Total Stock Mkt Idx

  •  

    247,726

  • 0.00

  • 1.31

  • Eurizon EasyFund Eq North America LTE

  •  

    169,018

  • 13.80

  • 0.89

  • Vanguard Extended Market Index Fund

  •  

    119,785

  • 4.81

  • 0.63

  • iShares Micro-Cap

  •  

    64,914

  • 0.00

  • 0.34

  • Fidelity Spartan® Extended Mkt Indx Fd

  •  

    57,904

  • 0.00

  • 0.31

  • Octalfa 360 Enjeux d'Avenir

  •  

    25,000

  • 0.00

  • 0.14

  • EB DL Non-SL Market Completion Fund

  •  

    12,810

  • 217.55

  • 0.07

  • Vanguard US Equity Index

  •  

    7,600

  • 0.00

  • 0.04

  • Fidelity Spartan® Total Market Idx Fund

  •  

    4,592

  • 0.00

  • 0.02

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Bridger Management LLC

  •  

    2,142,857

  • 0.00%

  • 11.34

  • Vanguard Group, Inc.

  •  

    365,262

  • +5.64%

  • 1.93

  • Morgan Stanley Smith Barney LLC

  •  

    352,319

  • +39.99%

  • 1.86

  • CAMBRIDGE Invest RESEARCH ADVISORS, INC.

  •  

    335,108

  • -3.65%

  • 1.77

  • Carnegie Asset Management Fondsmæglersel

  •  

    250,000

  • 0.00%

  • 1.30

  • Eurizon Capital S.A.

  •  

    169,023

  • +13.80%

  • 0.89

  • BlackRock Fund Advisors

  •  

    69,623

  • +2.95%

  • 0.37

  • Geode Capital Management, LLC

  •  

    65,494

  • 0.00%

  • 0.35

  • Denver Investments

  •  

    43,541

  • +126.80%

  • 0.23

  • Northern Trust Investments, N.A.

  •  

    32,897

  • -1.64%

  • 0.17

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Distressed

Style

Small Value

TrovaGene, Inc., was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology....more As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for ...morethe detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a strong intellectual property portfolio. The Company’s developed significant intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, our property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by our growing patent estate. Its competitors include medical diagnostic companies, most of which have financial, technical, and marketing resources significantly greater than our resources.lessless

Key People

Dr. Antonius Schuh,PhD

CEO/Director

Dr. Thomas H. Adams,PhD

Chairman of the Board/Director

Stephen Zaniboni

CFO/Chief Accounting Officer

Dr. Rodney S. Markin,M.D.,PhD

Director

Gary S. Jacob

Director

Incorporated

2002

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: